1 July 2020 in Future Cardiology
The adipose tissue, apart from storing energy, plays a role of an endocrine organ. One of the most important adipokines secreted by adipose tissue is adiponectin, which is also produced by cardiomyocytes and connective tissue cells within the heart. Adiponectin is known for its beneficial effect on the metabolism and cardiovascular system and its low level is a factor of development of many cardiovascular diseases. Paradoxically, in the course of heart failure, adiponectin level gradually increases with the severity of the disease and higher adiponectin level is a factor of poor prognosis. As a result, there is a growing interest in adiponectin as a marker of heart failure progression and a predictor of prognosis in the course of this disease.
1 June 2016 in Transplantation Proceedings
7 September 2018 in Polish Heart Journal
Background: Due to the increasing number of patients placed on waiting lists for orthotopic heart transplantation (OHT), the selection of patients with the highest risk of death becomes paramount. Aim: This study sought to evaluate the predictive value of the MELD-XI (Model for End-Stage Liver Disease excluding INR) and MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) scales in ambulatory patients awaiting OHT and compare them to the HFSS (Heart Failure Survival Score). Methods: The study was a retrospective review of 370 adult ambulatory patients with end-stage HF who were admitted to the OHT waiting list at our institution between 2012 and 2016. Results: The median age of the patients was 54.0 (46.0–60.0) years, and 324 (87.6%) of them were male. The overall one–year mortality was 27.6%. The areas under the curves (AUCs) for the MAGGIC and HFSS scales were comparable [0.771 (95%CI: 0.720–0.823); sensitivity 77%, specificity 68% vs. 0.781 (95%CI: 0.732–0.829); sensitivity 90 %, specificity 58%, respectively]. The AUC for the MELD–XI scale was higher than that for the HFSS scale [0.812 (95%CI: 0.769–0.856); sensitivity 91%, specificity 63% vs. 0.781 (95%CI: 0.732–0.829) sensitivity 90%, specificity 58%, respectively]. Conclusions: Our study demonstrated that elevated MELD-XI and MAGGIC scores and lowered HFSS scores were associated with an increased risk of death during the one-year follow-up. The prognostic utility of the MELD-XI scoring system was better than that of the HFSS scale, while the MAGGIC scale was comparable to the HFSS. Background: Due to the increasing number of patients placed on waiting lists for orthotopic heart transplantation (OHT), the selection of patients with the highest risk of death becomes paramount. Aim: This study sought to evaluate the predictive value of the MELD-XI (Model for End-Stage Liver Disease excluding INR) and MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) scales in ambulatory patients awaiting OHT and compare them to the HFSS (Heart Failure Survival Score). Methods: The study was a retrospective review of 370 adult ambulatory patients with end-stage HF who were admitted to the OHT waiting list at our institution between 2012 and 2016. Results: The median age of the patients was 54.0 (46.0–60.0) years, and 324 (87.6%) of them were male. The overall one–year mortality was 27.6%. The areas under the curves (AUCs) for the MAGGIC and HFSS scales were comparable [0.771 (95%CI: 0.720–0.823); sensitivity 77%, specificity 68% vs. 0.781 (95%CI: 0.732–0.829); sensitivity 90 %, specificity 58%, respectively]. The AUC for the MELD–XI scale was higher than that for the HFSS scale [0.812 (95%CI: 0.769–0.856); sensitivity 91%, specificity 63% vs. 0.781 (95%CI: 0.732–0.829) sensitivity 90%, specificity 58%, respectively]. Conclusions: Our study demonstrated that elevated MELD-XI and MAGGIC scores and lowered HFSS scores were associated with an increased risk of death during the one-year follow-up. The prognostic utility of the MELD-XI scoring system was better than that of the HFSS scale, while the MAGGIC scale was comparable to the HFSS.
26 October 2010 in Cardiology
Objective: This study aimed to investigate the usefulness of the calcium-channel blocker verapamil in non-advanced dilated cardiomyopathy (DCM). Methods: This was a randomised trial of 70 DCM patients treated with carvedilol (36 patients) and verapamil (instead of β-blocker; 34 patients) for 12 months. The remaining heart failure (HF) therapy was constant in both groups. The primary outcomes were to determine selected echocardiography parameters and functional status of patients. The secondary outcome included death, heart transplantation and re-hospitalisation due to HF progression. Results: Of the primary outcomes, only the mean ratio of early to late transmitral flow velocities increased significantly in the verapamil-treated patients as compared with the carvedilol-based therapy (1.1 ± 0.3 vs. 0.7 ± 0.2; 95% CI –0.6 to –0.1; p = 0.015). Simultaneously, the Minnesota Quality of Life improved significantly in the verapamil group (95% CI 5.2–19.9; p = 0.002). It was accompanied by the favourable effect of verapamil therapy on exercise capacity in the 6-min walk test (95% CI 21.3–110.7; p = 0.005). Conclusion: The addition of verapamil to angiotensin-converting enzyme and aldosterone inhibitors in non-advanced DCM patients has been shown to have a neutral or even positive effect in a few patients.
7 May 2020 in American Journal of Transplantation
Cardiac allograft vasculopathy (CAV) still is one of the most important limiting factors of long‐term survival following heart transplantation (HT). This study aimed to investigate the association between proinflammatory adipokine‐visfatin and the incidence of CAV in HT recipients. 182 patients after HT who had a follow‐up visit at the Transplantation Clinic between 2016 and 2017 were analyzed. The median age was 60.5 years and 76.4% were men. The incidence of CAV was 54.9%. According to the multivariable proportional hazard regression analysis, visfatin level [1.795 (1.539‐2.094); p<0.001] was significantly associated with CAV, and statin use was protective against CAV [0.504 (0.32‐0.793); p=0.003]. The area under the receiver operating characteristic curve indicated an excellent discriminatory power of visfatin [0.9548 (0.9281‐0.9816)] for CAV detection. The cut‐off value of 5.42 ng/mL for visfatin yielded a sensitivity of 89% and specificity of 91%. This is the first study to demonstrate that visfatin serum concentrations are independently associated with the incidence of CAV in HT recipients. Visfatin allows for simple and cheap detection of CAV given its excellent discriminatory ability and high sensitivity and specificity. In addition, we have found an independent association between the lack of statins use and a higher risk of CAV.